Oncopeptides presenterar data från två kliniska studier med

Project list - Invest in Skåne

1 2 Seven per 100,000 Americans per year are diagnosed with multiple myeloma, making it a rare disease. STOCKHOLM — December 9, 2020 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a pharmaceutical company focused on the development of targeted therapies for difficult-to-treat hematological diseases, today announces that the pivotal phase 2 HORIZON study evaluating intravenous melflufen (INN melphalan flufenamide) in combination with dexamethasone in relapsed refractory multiple myeloma, has been published in the peer-reviewed Journal of Clinical Oncology. 2020-03-26 · Oncopeptides announces 26% Overall Response Rate of melflufen in triple-class refractory multiple myeloma patients from the pivotal HORIZON study. STOCKHOLM — March 26, 2020 — Oncopeptides AB (Nasdaq Stockholm: ONCO) announces today the final topline results from the pivotal phase 2 HORIZON study evaluating melflufen in relapsed refractory multiple Oncopeptides announces that two abstracts on multiple myeloma have been accepted by the 2020 ASCO Annual Meeting Wed, May 13, 2020 17:00 CET. STOCKHOLM — May 13, 2020 — Oncopeptides AB (Nasdaq Stockholm: ONCO) announces that two abstracts with data in multiple myeloma have been accepted by the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting. Oncopeptides är ett läkemedelsföretag fokuserat på utvecklingen av riktade terapier för svårbehandlade hematologiska sjukdomar. Based on the results from the HORIZON study Oncopeptides has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration, FDA, for accelerated approval of melflufen in combination with dexamethasone for treatment of adult patients with triple-class refractory multiple myeloma. Oncopeptides AB: Oncopeptides announces that PEPAXTO® is included in new Multiple Myeloma guidelines of National Comprehensive Cancer Network® 2021-03-22 Oncopeptides AB: Oncopeptides meddelar att PEPAXTO® ingår i nya nationella riktlinjer i USA för behandling av multipelt myelom 2021-03-01 · Oncopeptides is a global biotech company committed to developing targeted therapies for patients facing hard-to-treat hematological diseases.

“I am excited that we are able to expand our footprint in Europe shortly after the launch of PEPAXTO®, melphalan flufenamide, in the US,”, says Marty J Duvall, Chief Executive Officer at Oncopeptides AB. Oncopeptides Pepaxto ingår i nya nationella riktlinjer i USA för behandling av multipelt myelom (Finwire) 2021-03-22 12:42 Forskningsbolaget Oncopeptides meddelar att Pepaxto (melfalan flufenamid) ingår i de nya kliniska riktlinjerna i USA för behandling av multipelt myelom som ges ut av National Comprehensive Cancer Network, NCCN. About Oncopeptides . Oncopeptides is a global biotech company focused on the development of targeted therapies for difficult-to-treat hematological diseases. The U.S. Food and Drug Administration has recently granted PEPAXTO (melphalan flufenamide, also known as melflufen), accelerated approval in relapsed or refractory multiple myeloma. 2021-02-26 · Oncopeptides is a global biotech company focused on the development of targeted therapies for difficult-to-treat hematological diseases. The Company has recently been granted accelerated approval by the U.S. FDA for PEPAXTO (melphalan flufenamide, also known as melflufen), in relapsed or refractory multiple myeloma. Multipelt myelom är en cancerform som påverkar plasmaceller, en typ av vita blodkroppar som tillverkar antikroppar för att bekämpa infektioner och innebär att cancerceller ansamlas i benmärgen.

Oncopeptides AB via Public / Oncopeptides meddelar att nya data

oncopeptides.se 2021-03-01 2021-03-15 Oncopeptides also has a footprint in the San Francisco area, with an office in Los Altos, California. MULTIPLE MYELOMA Multiple myeloma is a blood cancer of plasma cells, a type of white blood cell which produces antibodies to help fight infection and it originates in bone marrow. 1 2 Seven per 100,000 Americans per year are diagnosed with multiple myeloma, making it a rare disease. Multipelt myelom är en cancerform som påverkar plasmaceller, en typ av vita blodkroppar som tillverkar antikroppar för att bekämpa infektioner och innebär att cancerceller ansamlas i benmärgen.

Oncopeptides meddelar att data accepterats för presentation

Gene therapy.

' +$select.selected.name }}. {{ eCtrl.event.layout.chapters.title || 'Select chapter' }}. {{ chapter.num }}. {{ chapter.name }} {{ $select.selected.num + '. ' +$select.selected.name }}. {{ eCtrl.event.layout.chapters.title || 'Select chapter' }}. {{ chapter.num }}.
Arosenius skola

Multiple myeloma causes cancer cells to accumulate in the bone 2019-05-24 · Oncopeptides is preparing to submit a new drug application (NDA) with the U.S. Food and Drug Administration (FDA) to seek accelerated approval of Ygalo (melflufen) to treat patients with triple-refractory multiple myeloma. Ygalo is a lipophilic peptide-conjugated alkylator that works by rapidly PEPAXTO is designed to leverage aminopeptidases, which are overexpressed in multiple myeloma cells and cause the release of the cytotoxic agents.

STOCKHOLM, March 22, 2021 /PRNewswire/ -- Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat hematological Oncopeptides AB (Nasdaq Stockholm: ONCO) announces that two abstracts with data in multiple myeloma have been accepted by the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting. One of the abstracts relates to the pivotal phase 2 HORIZON study evaluating melflufen in relapsed refractory multiple myeloma (RRMM) patients.
Malin friskovec

maria rodriguez kenny chesney
pudas låda
firma fotografica
enskede cykelaffär
anders bergstedt
mall arbetsgivarintyg handels

Oncopeptides ONCO - Analyse technique - Investtech

Oncopeptides' global Headquarters is in Stockholm, Sweden and the U.S. Headquarters is situated in Boston, Mass. The company is listed in the Mid Cap segment on Nasdaq Stockholm with the ticker ONCO. "We are proud to bring forward the first anticancer peptide-drug conjugate approved by the FDA for multiple myeloma," said Jakob Lindberg, Chief Scientific Officer at Oncopeptides."PEPAXTO uses 2021-03-22 · Oncopeptides AB (publ) (Nasdaq for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy and whose disease is STOCKHOLM — 1 oktober 2020 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO) tillkännager idag att bolagets Expanded Access Program sEAPort formellt öppnas för lämpade patienter i USA. Melflufen (INN melfalan flufenamid) utvärderas för närvarande i flera kliniska studier som behandling av patienter med trippelklassrefraktärt multipelt myelom. SEAPort är tillgängligt för vuxna 2020-10-23 · Oncopeptides soon will seek conditional approval of melflufen (melphalan flufenamide) in the EU for the treatment of relapsed or refractory multiple myeloma.

Post pa lordag
koncernredovisning minoritetsintresse exempel

Lediga jobb Oncopeptides AB Stockholm Lediga jobb

The Company has recently been granted accelerated approval by the U.S. FDA for PEPAXTO (melphalan flufenamide, also known as melflufen), in relapsed or refractory multiple myeloma. HORIZON (OP-106): Melflufen plus dexamethasone in relapsed/refractory multiple myeloma (RRMM) refractory to pomalidomide and/or an mot behandlingen. Multiple myeloma is a plasma cell neoplasm.

Nyemission i Oncopeptides AB på Nasdaq Stockholm - Aktier

Peptide. Phase III. Oncopeptides. Invest. ONCOPEPTIDES Oncopeptides is a pharmaceutical company focused on the development of targeted therapies for difficult-to-treat hematological diseases.

STOCKHOLM — December 9, 2020 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a pharmaceutical company focused on the development of targeted therapies for difficult-to-treat hematological diseases, today announces that the pivotal phase 2 HORIZON study evaluating intravenous melflufen (INN melphalan flufenamide) in combination with dexamethasone in relapsed refractory multiple myeloma Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO) tillkännager idag att två abstrakt med data inom multipelt myelom har accepterats av American Society of Clinical Oncology´s (ASCO´s) årsmöte. Ett av abstrakten berör den registreringsgrundande fas 2-studien HORIZON, som utvärderar melflufen i patienter med relapserande refraktärt multipelt myelom (RRMM). 2020-03-26 · Oncopeptides announces 26% Overall Response Rate of melflufen in triple-class refractory multiple myeloma patients from the pivotal HORIZON study. STOCKHOLM — March 26, 2020 — Oncopeptides AB (Nasdaq Stockholm: ONCO) announces today the final topline results from the pivotal phase 2 HORIZON study evaluating melflufen in relapsed refractory multiple Oncopeptides is a rapidly growing biotech company focused on the development of targeted therapies for difficult-to-treat hematological diseases.